Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Diagnostics Research Group, Diomics, Halleck-Willard, Icecure Medical, IMA Group, Integrated Media Technology, Magnum International, Nutriband, SPT Labtech, Steripack.
Although the need for COVID-19 boosters remains a tense debate among policymakers and scientific experts worldwide, the U.S. FDA is basing its Oct. 14-15 Vaccines and Related Biologics Products Advisory Committee meeting on the premise that vaccine boosters are needed.
Curevac AG, once a forerunner in COVID-19 vaccine development but later surpassed, said it would terminate its first effort in the field, CVnCoV, withdrawing it from a rolling review at the EMA to focus instead on development of second-generation mRNA vaccine candidates with Glaxosmithkline plc.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Athenex, Brii, Enzyvant, Genentech, Kintor, Merck, Protagonist, Regeneron, Ridgeback, Roche.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Aligos, Astrazeneca, Bicycle, Diurnal, Idorsia, Galmed, Oxurion, Regenxbio, Reistone, Repertoire, Sarepta.
Cambridge, U.K.-based Astrazeneca plc has new data from its long-acting COVID-19 antibody combination, AZD-7442, which aims to provide longer protection, potentially for up to a year. Latest data show the intramuscularly injected drug achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalized patients with mild to moderate symptomatic disease.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cytosorbents, Limflow, Medalliance, Todos Medical.